Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

John Nicholson

Internal Medicine Statesville, NC Medical Doctor

NPI 1497723795 CMS profile 248964

738 Bryant St, Statesville, NC 28677

Open in the dashboard

General payments

$6,603

418 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, John Nicholson of Statesville, NC is reported in the CMS Open Payments database as having received $6,603 across 418 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $529 28
2024 General $600 34
2023 General $1,444 83
2022 General $1,345 89
2021 General $1,122 70
2020 General $963 60
2019 General $601 54

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Nicholson
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to John Nicholson were reported at $529. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year John Nicholson Internal Medicine median Middle half National median
2019 $601 $159 $48–$570 $163
2020 $963 $119 $33–$402 $114
2021 $1,122 $135 $37–$521 $132
2022 $1,345 $141 $42–$496 $149
2023 $1,444 $149 $45–$519 $160
2024 $600 $154 $47–$537 $164
2025 $529 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Lilly USA, LLC $806 52 payments
  2. AstraZeneca Pharmaceuticals LP $794 42 payments
  3. Novo Nordisk Inc $787 70 payments
  4. Pfizer Inc. $705 44 payments
  5. Amgen Inc. $491 33 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $440 29 payments
  7. Janssen Pharmaceuticals, Inc $422 26 payments
  8. Bayer HealthCare Pharmaceuticals Inc. $326 21 payments
  9. Mylan Specialty L.P. $325 19 payments
  10. Sanofi-Aventis U.S. LLC $209 13 payments
  11. Other $1,298 69 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,603 418 payments
Products named General payments · program years 2019–2025
  1. FARXIGA $554 29 payments
  2. Ozempic $523 46 payments
  3. ELIQUIS $489 31 payments
  4. XARELTO $395 25 payments
  5. JARDIANCE Diabetes $388 24 payments
  6. RYBELSUS $383 30 payments
  7. MOUNJARO $333 22 payments
  8. JARDIANCE Diabetes $330 23 payments
  9. Kerendia $326 21 payments
  10. Repatha $283 19 payments
  11. Other $5,242 319 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 172 drugs

Part D claims

11,982

Median for Internal Medicine: 777

Drug cost

$1,061,032

Median for Internal Medicine: $73,373

Branded share of claims

23.1%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 142 $116,635
Ozempic Semaglutide Brand 89 $114,448
Mounjaro Tirzepatide Brand 78 $97,715
Jardiance Empagliflozin Brand 98 $91,368
Soliqua 100-33 Insulin Glargine/Lixisenatide Brand 89 $85,526
Xarelto Rivaroxaban Brand 66 $66,104
Trulicity Dulaglutide Brand 39 $53,106
Tresiba Flextouch U-200 Insulin Degludec Brand 23 $50,528
Farxiga Dapagliflozin Propanediol Brand 54 $46,758
Tradjenta Linagliptin Brand 23 $23,921

The 10 drugs with the highest cost, of 172 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 49 billing codes

Paid by Medicare

$69,498

Of which drugs: $7,808

Medicare patients

221

Average age 76

Services billed

1,427

123 women, 98 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 44%
Diabetes 31%
Ischemic heart disease 26%
Atrial fibrillation 21%
Chronic kidney disease 20%
Depression 19%
COPD 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 15 15 $4,052
Vaccine for influenza for injection into muscle 90653 Office 42 42 $3,355
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 36 299 $213

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $50
  • Lilly USA, LLC $35
$85 98 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $76
$76 — —
MOUNJARO
  • Lilly USA, LLC $56
$56 78 —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $48
$48 — —
Qutenza
  • Averitas Pharma Inc. $27
$27 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

418 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record